Media stories about Calithera Biosciences (NASDAQ:CALA) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Calithera Biosciences earned a daily sentiment score of 0.07 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.8671141041923 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Calithera Biosciences traded down $0.25, hitting $5.15, during trading hours on Tuesday, according to MarketBeat Ratings. 498,674 shares of the company’s stock traded hands, compared to its average volume of 498,104. The firm has a market capitalization of $189.98 million, a price-to-earnings ratio of -6.13 and a beta of 2.53. Calithera Biosciences has a 52 week low of $4.70 and a 52 week high of $20.05.
Calithera Biosciences (NASDAQ:CALA) last announced its earnings results on Thursday, May 10th. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.05). The business had revenue of $5.19 million for the quarter, compared to the consensus estimate of $7.28 million. Calithera Biosciences had a negative net margin of 131.51% and a negative return on equity of 22.92%. analysts predict that Calithera Biosciences will post -1.4 EPS for the current fiscal year.
A number of brokerages have recently commented on CALA. Zacks Investment Research lowered shares of Calithera Biosciences from a “hold” rating to a “sell” rating in a research note on Tuesday, March 13th. ValuEngine upgraded shares of Calithera Biosciences from a “sell” rating to a “hold” rating in a research note on Wednesday, June 20th. Finally, Leerink Swann reiterated an “outperform” rating on shares of Calithera Biosciences in a research note on Friday, April 6th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $16.50.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.